CANY
AGIO icon

Caxton Associates (New York)’s Agios Pharmaceuticals AGIO Stock Holding History

Caxton Associates (New York)’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,544
Closed -$380K – 485
2024
Q3 		$380K Sell
8,544
-28,909
-77% -$1.31M 0.01% 405
2024
Q2 		$1.61M Buy
37,453
+264
+0.7% +$9.53K 0.06% 184
2024
Q1 		$1.09M Buy
+37,189
New +$996K 0.06% 208
2023
Q1 		– Sell
-13,959
Closed -$392K – 486
2022
Q4 		$392K Sell
13,959
-9,501
-40% -$268K 0.03% 288
2022
Q3 		$663K Buy
23,460
+2,232
+11% +$59.9K 0.09% 184
2022
Q2 		$471K Buy
+21,228
New +$479K 0.05% 287

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Caxton Associates (New York)'s AGIO Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Agios Pharmaceuticals (AGIO) in Q4 2024, closing a stake of 8,544 shares — an estimated $380K sold.

Caxton Associates (New York) first reported a position in AGIO in Q2 2022 and held it in 6 quarters. The position peaked at $1.61M in Q2 2024. 225 funds tracked by Wall St. Rank hold AGIO as of Q4 2024.

  • Caxton Associates (New York) reported no remaining Agios Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 8,544 Agios Pharmaceuticals shares in Q4 2024, an estimated $380K.
  • Caxton Associates (New York) first reported a position in Agios Pharmaceuticals in Q2 2022 and held it in 6 quarters.
  • Caxton Associates (New York)'s Agios Pharmaceuticals position peaked at $1.61M in Q2 2024.
  • 225 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.